Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CCR6 | P51684 | 1/20 | 0.46 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6751575 | 1.00 | TACR1 (0.51) | TACR1LMNAMEN1PKMKMT2A | |
| SCHEMBL27462559 | 1.00 | TACR1 (0.51) | TACR1LMNAMEN1PKMKMT2A | |
| SCHEMBL7192154 | 0.85 | ALDH1A1 (0.56) | LMNAMEN1KMT2AALDH1A1CYP2D6 | |
| SCHEMBL3823774 | 0.85 | ITGA4 (0.50) | ALDH1A1NPC1 | |
| SCHEMBL4733108 | 0.85 | ITGA4 (0.50) | ALDH1A1NPC1 | |
| SCHEMBL2780433 | 0.85 | CYP2D6 (0.49) | ALDH1A1CYP2D6CYP2C9CYP2C19RECQL | |
| SCHEMBL6193349 | 0.85 | CYP2D6 (0.49) | ALDH1A1CYP2D6CYP2C9CYP2C19RECQL | |
| SCHEMBL6194780 | 0.85 | CYP2D6 (0.49) | ALDH1A1CYP2D6CYP2C9CYP2C19RECQL | |
| SCHEMBL6190821 | 0.85 | CYP2D6 (0.49) | ALDH1A1CYP2D6CYP2C9CYP2C19RECQL | |
| SCHEMBL6190824 | 0.85 | CYP2D6 (0.49) | ALDH1A1CYP2D6CYP2C9CYP2C19RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6953780-B2 | Endothelin antagonist | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES, P.L.A. (CN) | 2005-10-11 | — | — | US | disclosed |
| CN-1202096-C | 2-aminothiazoline derivatives and their use as no-synthase inhibitors | AVENTIS PHARMA SA (FR) | 2005-05-18 | — | — | CN | disclosed |
| US-6833382-B2 | By muta-synthesis using a mutated micro-organism to influence the biosynthesis of at least one of the precursors of group B streptogramines; mutant strain employed is preferably derived from the strain S. pristinaespiralis SP92 | AVENTIS PHARMA S.A. (FR) | 2004-12-21 | — | — | US | disclosed |
| CN-1160368-C | Endothelin antegon | 中国人民解放军军事医学科学院毒物药 | 2004-08-04 | — | — | CN | disclosed |
| CN-1155612-C | Endothelin antagon | 中国人民解放军军事医学科学院毒物药 | 2004-06-30 | — | — | CN | disclosed |
| CN-1155611-C | Endothelin antagon | 中国人民解放军军事医学科学院毒物药 | 2004-06-30 | — | — | CN | disclosed |
| US-20040038906-A1 | Tripeptides; acidification; saponification | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES, P.L.A. (CN) | 2004-02-26 | — | — | US | disclosed |
| CN-1444572-A | 2-aminothiazoline derivatives and their use as no-synthase inhibitors | AVENTIS PHARMA SA (FR) | 2003-09-24 | — | — | CN | disclosed |
| US-20020142947-A1 | STREPTOGRAMINS AND METHOD FOR PREPARING SAME BY MUTASYNTHESIS | AVENTIS PHARMA, S.A. | 2002-10-03 | — | — | US | disclosed |
| US-6352839-B1 | PREPARING VIRGINIAMYCINS FROM AN ENGINEERED MICROORGANISMS, HAVING THE ABILITY TO PREVENT BIOSYNTHESIS OF THE PRECURSOR ANTIBIOTIC; THE MICROORGANISM IS CULTURED IN THE PRESENCE OF A SECOND PRECURSOR AND THE STREPTOGRAMIN ANALOG IS RECOVERED | AVENTIS PHARMA S.A. (FR) | 2002-03-05 | — | — | US | disclosed |
| CN-1330077-A | Endothelin antegon | INST OF TOXIC MEDICINES PLA S (CN) | 2002-01-09 | — | — | CN | disclosed |
| CN-1330076-A | Endothelin antagon | INST OF TOXIC MEDICINES PLA S (CN) | 2002-01-09 | — | — | CN | disclosed |
| CN-1330075-A | Endothelin antagon | INST OF TOXIC MEDICINES PLA S (CN) | 2002-01-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020142947-A1 | STREPTOGRAMINS AND METHOD FOR PREPARING SAME BY MUTASYNTHESIS | EMG1, FBL, SMS | TACR1 4703/4885LMNA 929/4885MEN1 364/4885 |
| US-20040038906-A1 | Tripeptides; acidification; saponification | VIP, DNPEP, ECE1 | TACR1 269/4885LMNA 476/4885MEN1 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.